Improving the production of viral vectors using advanced cell culture techniques
Continuous Production of Viral Vectors using membraneless Perfusion Culture of Host Cells
This study is looking at a new way to grow special cells that help make vaccines and gene therapies better, which could lead to improved treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10694916 on NIH RePORTER |
What this research studies
This research focuses on enhancing the production of viral vectors, which are crucial for gene therapy and vaccine development, by utilizing a novel membrane-less perfusion bioreactor system. This innovative approach allows for continuous cultivation of host cells at high densities while efficiently removing dead cells and debris, ensuring optimal conditions for viral vector production. The team will explore various production platforms and optimize processes to improve both the quantity and quality of the viral vectors produced. Patients may benefit from advancements in gene therapies and vaccines that rely on these viral vectors.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with conditions that could be treated with gene therapies or vaccines developed using these viral vectors.
Not a fit: Patients who are not seeking gene therapy or vaccine options may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more efficient and higher-quality production of viral vectors, potentially improving gene therapy and vaccine development for patients.
How similar studies have performed: Other research has shown promise in improving viral vector production using advanced bioreactor systems, indicating that this approach may lead to significant advancements.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Han, Jongyoon — Massachusetts Institute of Technology
- Study coordinator: Han, Jongyoon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.